Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo

Inclusion criteria

• Patients with mild gingivitis (mean GI: 0.2 - 1.0)
• Patients with complete natural "Ramfjord-teeth" or their replacement teeth
• Caucasian
• Signed Informed Consent

Exclusion criteria

• Patients with severe systemic diseases (diabetes, hepatitis, HIV, tuberculosis, cancer)
• Patients who require endocarditis prophylaxis for dental examination and treatment
• Caries requiring treatment (e.g. caries with cavity) or other oral diseases (incl. gingival hyperplasia, diseases of the oral mucosa, periodontal screening index PSI > 2)
• Patients with orthodontic appliances and removable dentures
• Patients treated with antibiotics less than 3 months prior to the baseline examination at V1 and/or such a treatment planned for the duration of the trial
• Patients chronically treated with steroids
• Patients who suffer from xerostomia
• Patients who regularly smoke more than 10 cigarettes per day
• Patients who have a known hypersensitivity or allergy to the test product and its ingredients or to medications that have a similar chemical structure
• Participation of the patient in another clinical trial within the last four weeks before enrollment in this trial
• Incapability of assessing essence and possible consequences of the trial (e.g. alcoholism)
• Pregnant or breastfeeding women
• Women with childbearing potential except those who fulfill the following criteria:

• Post-menopausal (12 month of natural amenorrhoea or 6 months of amenorrhoea with Serum FSH > 40 U/ml)
• Postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy)
• Continuous and correct application of a contraception method with a Pearl Index < 1% (e.g. implants, depots, oral contraceptives, intrauterine device - IUD)